Interim results from ADmirable, a phase 3b open-label study assessing lebrikizumab in patients with skin of color and moderate-to-severe atopic dermatitis

被引：0

作者：

Alexis, Andrew ^{[1
]}

Moiin, Ali ^{[2
]}

Waibel, Jill ^{[3
]}

Wallace, Paul ^{[4
]}

Cohen, David ^{[5
]}

Laquer, Vivian ^{[6
]}

Kwong, Pearl ^{[7
]}

Atwater, Amber Reck ^{[8
]}

Harris, Cynthia ^{[8
]}

Proper, Jennifer ^{[8
]}

Silk, Maria ^{[8
]}

Pierce, Evangeline ^{[8
]}

Pillai, Sreekumar ^{[8
]}

Rueda, Maria Jose ^{[8
]}

Moore, Angela ^{[9
,10
,11
]}

机构：

[1] Weill Cornell Med, New York, NY USA

[2] Comprehens Dermatol Ctr, Detroit, MI USA

[3] Miami Dermatol & Laser Inst, Miami, FL USA

[4] Wallace Skin Res Ctr, Los Angeles, CA USA

[5] Skin Care Phys Georgia, Macon, GA USA

[6] First OC Dermatol Res, Fountain Valley, CA USA

[7] Suncoast Skin Solut Inc, Jacksonville, FL USA

[8] Eli Lilly & Co, Indianapolis, IN USA

[9] Baylor Univ, Med Ctr, Dallas, TX USA

[10] Arlington Res Ctr, Arlington, TX USA

[11] Arlington Ctr Dermatol, Arlington, TX USA

来源：

关键词：

atopic dermatitis; disease severity; ethnicity; lebrikizumab; race;

D O I：

10.1093/bjd/ljae266.099

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：102 / 103

页数：2